GenCurix Obtains Japanese Patent for Prognostic Diagnosis of Breast Cancer in Asians

[Asia Economy Reporter Hyungsoo Park] Genetic diagnostics company GenCurix announced on the 8th that it has completed the registration of a Japanese patent for its breast cancer prognosis diagnostic product 'Jinswell BCT,' developed using proprietary technology.

The patent pertains to a method for predicting the prognosis of breast cancer patients by measuring the expression values of specific genes within breast cancer tissue to predict the risk of recurrence and metastasis in patients.

Based on the patent registration, GenCurix plans to accelerate the approval process of Jinswell BCT with the Japanese Pharmaceuticals and Medical Devices Agency (PMDA).

A company representative stated, "Since our technology has been recognized for its originality in Japan and intellectual property protection issues have been resolved, we plan to actively pursue entry into the Japanese market."

Jinswell BCT is the first breast cancer prognosis prediction test kit to confirm clinical efficacy targeting Asian patients and to receive formal approval from national authorities. Unlike existing breast cancer diagnostic products developed targeting Caucasian patients, Jinswell BCT has demonstrated accuracy for Asian patients through multiple clinical trials involving Korean and Japanese patients. While competing products typically require 3 to 4 weeks for testing, Jinswell BCT can provide results within 7 days. It also allows for coverage under indemnity insurance, reducing the financial burden on patients.

This content was produced with the assistance of AI translation services.